Marina Publishes Data from Bladder Cancer Program Showing 'Significant' Tumor Reduction with UsiRNAs

The paper comes out about a month after Marina exclusively licensed the program to Switzerland's Debiopharm, which is responsible for all related development and commercialization activities, for up to $25 million, plus royalties.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.